PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-10.89%
Negative revenue growth while AVGO stands at 5.51%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-14.65%
Negative gross profit growth while AVGO is at 4.31%. Joel Greenblatt would examine cost competitiveness or demand decline.
-17.85%
Negative EBIT growth while AVGO is at 6.66%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-18.75%
Negative operating income growth while AVGO is at 6.66%. Joel Greenblatt would press for urgent turnaround measures.
-14.51%
Negative net income growth while AVGO stands at 9.27%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-13.94%
Negative EPS growth while AVGO is at 10.96%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-13.77%
Negative diluted EPS growth while AVGO is at 8.45%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.77%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.76%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
7.68%
Dividend growth above 1.5x AVGO's 4.77%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-26.17%
Negative OCF growth while AVGO is at 3.59%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-45.60%
Negative FCF growth while AVGO is at 3.55%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
92.58%
10Y revenue/share CAGR under 50% of AVGO's 764.88%. Michael Burry would suspect a lasting competitive disadvantage.
35.39%
5Y revenue/share CAGR under 50% of AVGO's 83.01%. Michael Burry would suspect a significant competitive gap or product weakness.
43.56%
3Y revenue/share CAGR at 75-90% of AVGO's 49.34%. Bill Ackman would expect new product strategies to close the gap.
131.20%
10Y OCF/share CAGR under 50% of AVGO's 1175.86%. Michael Burry would worry about a persistent underperformance in cash creation.
15.09%
Below 50% of AVGO's 132.24%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
19.89%
3Y OCF/share CAGR under 50% of AVGO's 78.58%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
812.98%
Net income/share CAGR at 50-75% of AVGO's 1164.46%. Martin Whitman might question if the firm’s product or cost base lags behind.
520.08%
5Y net income/share CAGR 1.25-1.5x AVGO's 424.29%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
88.83%
Below 50% of AVGO's 283.07%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
63.37%
Below 50% of AVGO's 461.90%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
53.31%
5Y equity/share CAGR above 1.5x AVGO's 10.57%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
68.54%
Positive short-term equity growth while AVGO is negative. John Neff sees a strong advantage in near-term net worth buildup.
487.06%
Below 50% of AVGO's 2634.87%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
99.82%
Below 50% of AVGO's 325.24%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
37.51%
3Y dividend/share CAGR at 50-75% of AVGO's 63.31%. Martin Whitman might see a weaker short-term approach to distributing cash.
-7.11%
Firm’s AR is declining while AVGO shows 9.23%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
14.68%
Inventory growth well above AVGO's 4.73%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
4.41%
Asset growth above 1.5x AVGO's 2.70%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
1.26%
Under 50% of AVGO's 10.89%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
14.39%
Debt growth far above AVGO's 0.05%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
0.70%
We increase R&D while AVGO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-0.46%
We cut SG&A while AVGO invests at 14.55%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.